Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study
Analyse der Langzeitnachbeobachtung einer randomisierten klinischen Studie mit Abweichungen von den zugewiesenen Behandlungen: Schätzung der Metformin-Effekte auf Diabetes und seine Komplikationen in der Diabetes Prevention Program Outcomes Study
Diabetes Care · 01.10.2025 · 48 (10) · 1668-1675
DOI: 10.2337/dci25-0032 ↗Auf einen Blick
Die DPPOS untersuchte über 22 Jahre Metformin bei Hochrisiko-Erwachsenen. Metformin senkte die Diabetesinzidenz; für andere Outcomes änderten die Analysen die Schlussfolgerungen gegenüber der Intention-to-treat-Analyse nicht.
Fragestellung
Welche Langzeiteffekte von Metformin auf Diabetes und diabetesbezogene Komplikationen zeigen sich nach Abweichungen von der ursprünglichen Behandlungszuweisung?
Methode
Langzeitnachbeobachtung einer 3-jährigen RCT; Auswertung der DPPOS über 22 Jahre mit statistischen Methoden zur Schätzung von Interventionseffekten trotz Behandlungsänderungen.
Ergebnisse
Metformin reduzierte die Diabetesinzidenz konsistent. Für alle anderen Outcomes ergaben die Analysen ähnliche Effektschätzungen; die 95 %-KI der Hazard Ratios schlossen 1,0 ein.
Einschränkungen
Abweichungen von der ursprünglichen Zuweisung nach Diabetesentwicklung; für alle Outcomes außer Diabetesinzidenz lagen die 95 %-KI der Hazard Ratios um 1,0.
Schlussfolgerung der Autor:innen
Die Bestimmung der langfristigen Rolle von Metformin zur Minderung diabetesbezogener Komplikationen über die Diabetesprävention hinaus ist schwierig.
Kernaussagen
- Metformin senkte die Diabetesinzidenz konsistent.
- Für andere Outcomes blieb der Effekt unklar.
- Die Behandlungsänderungen erschwerten die Langzeitanalyse.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 26.08.2025. Verfasst von William C Knowler und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Metformin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, National Institute on Aging.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The Diabetes Prevention Program (DPP) was a 3-year randomized clinical trial (RCT) with evaluation of lifestyle and metformin interventions compared with placebo for diabetes prevention in high-risk adults. Both interventions significantly reduced diabetes incidence, prompting the long-term Diabetes Prevention Program Outcomes Study (DPPOS) to assess the progression of diabetes and its complications over 22 years. During follow-up, departures from the original metformin or placebo assignment occurred primarily because of development of diabetes that, by protocol, was managed by clinicians outside the study, after participants developed diabetes with HbA1c ≥7.0%. Diabetes development led to changes in metformin treatment and addition of other glucose-lowering therapies. Using statistical methods designed to estimate intervention effects despite these deviations, we consistently found that metformin reduced diabetes incidence. However, using these methods to evaluate whether use of metformin for prediabetes confers continued benefits after diabetes diagnosis did not substantially change the conclusions from those of the simpler intention-to-treat analysis that did not account for treatment changes. All of the analytic methods used resulted in similar metformin effect estimates with 95% CIs for hazard ratios including 1.0 (no effect) for all outcomes except for diabetes incidence. Elucidating metformin’s long-term role in mitigating diabetes-related complications beyond its effects on diabetes prevention is challenging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
- Departments of Pediatrics and Epidemiology and Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO.
- Division of Metabolism, Endocrinology and Nutrition, University of Washington, and VA Puget Sound Health Care System, Seattle, WA.
- Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
- Departments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, NY.
- Department of Internal Medicine, Health Sciences Center, University of New Mexico, Albuquerque, NM.
ORCID-Profile: William C Knowler, Qing Pan, Dana Dabelea, Sharon L Edelstein, Steven E Kahn, Shihchen Kuo, Vallabh Shah, Amisha Wallia, Marinella Temprosa
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Knowler, W. C., Pan, Q., Shu, S., Tripputi, M. T., Dabelea, D., Edelstein, S. L., Kahn, S. E., Kuo, S., Luchsinger, J. A., Shah, V., Wallia, A., Temprosa, M., & Diabetes Prevention Program Research Group (2025). Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 48(10), 1668-1675. https://doi.org/10.2337/dci25-0032
Vancouver
Knowler WC, Pan Q, Shu S, Tripputi MT, Dabelea D, Edelstein SL, et al. Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2025;48(10):1668-1675. doi:10.2337/dci25-0032
BibTeX
@article{Knowler2025,
author = {Knowler, William C and Pan, Qing and Shu, Shiyu and Tripputi, Mark T and Dabelea, Dana and Edelstein, Sharon L and Kahn, Steven E and Kuo, Shihchen and Luchsinger, José A and Shah, Vallabh and Wallia, Amisha and Temprosa, Marinella and Diabetes Prevention Program Research Group, Diabetes Prevention Program Research Group},
title = {Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study},
journal = {Diabetes Care},
year = {2025},
volume = {48},
number = {10},
pages = {1668--1675},
doi = {10.2337/dci25-0032}
}
EUVIMED